TY - JOUR
T1 - Renal artery stenosis
T2 - If and when to intervene
AU - Textor, Stephen C.
AU - McKusick, Michael M.
N1 - Funding Information:
The authors would like to thank Beverly Tietje for her coordination of the clinical studies described in this report. The work described was supported by Award Number R01 DK100081 from the National Institute for Diabetes, Digestive and Kidney Diseases (NIDDK) and NIH/NCRR CTSA Grant Number UL1 RR024150. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIDDK or the National Institutes of Health.
Publisher Copyright:
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Purpose of review: Atherosclerotic renovascular disease remains highly prevalent and presents an array of clinical syndromes. Recent prospective trials have dampened enthusiasm for revascularization generally, but clinicians recognize the need to identify patients likely to benefit from vascular intervention. Recent findings: This article highlights the inflammatory nature of vascular occlusive disease and the limits of the kidney to adapt to reduced blood flow. Although moderate reductions can be tolerated, severe impairment of renal perfusion leads to tissue hypoxia and activates inflammatory injury within the kidney. Hence, assessment of kidney viability and potential tools to modify mitochondrial and inflammatory damage may be important to identify patients for whom clinical intervention should be undertaken. Summary: Clinicians must recognize clinical syndromes that identify 'high-risk' groups and apply revascularization in those likely to benefit. Future efforts to protect the kidney (e.g., mitochondrial protection) or cell-based therapy may amplify clinical recovery when combined with restoring renal blood flow.
AB - Purpose of review: Atherosclerotic renovascular disease remains highly prevalent and presents an array of clinical syndromes. Recent prospective trials have dampened enthusiasm for revascularization generally, but clinicians recognize the need to identify patients likely to benefit from vascular intervention. Recent findings: This article highlights the inflammatory nature of vascular occlusive disease and the limits of the kidney to adapt to reduced blood flow. Although moderate reductions can be tolerated, severe impairment of renal perfusion leads to tissue hypoxia and activates inflammatory injury within the kidney. Hence, assessment of kidney viability and potential tools to modify mitochondrial and inflammatory damage may be important to identify patients for whom clinical intervention should be undertaken. Summary: Clinicians must recognize clinical syndromes that identify 'high-risk' groups and apply revascularization in those likely to benefit. Future efforts to protect the kidney (e.g., mitochondrial protection) or cell-based therapy may amplify clinical recovery when combined with restoring renal blood flow.
KW - flash pulmonary edema
KW - hypertension
KW - ischemic nephropathy
KW - renal artery stenosis
KW - renovascular hypertension
KW - stent
UR - http://www.scopus.com/inward/record.url?scp=84957427727&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957427727&partnerID=8YFLogxK
U2 - 10.1097/MNH.0000000000000202
DO - 10.1097/MNH.0000000000000202
M3 - Review article
C2 - 26741885
AN - SCOPUS:84957427727
SN - 1062-4821
VL - 25
SP - 144
EP - 151
JO - Current Opinion in Nephrology and Hypertension
JF - Current Opinion in Nephrology and Hypertension
IS - 2
ER -